Citigroup
ACTU

Citigroup’s Actuate Therapeutics ACTU Stock Holding History

Citigroup’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$604 Sell
395
-103
-21% -$239 ﹤0.01% 5447
2026
Q1 		$1.36K Buy
498
+283
+132% +$1.17K ﹤0.01% 5453
2025
Q4 		$1.32K Sell
215
-45
-17% -$309 ﹤0.01% 5516
2025
Q3 		$1.74K Sell
260
-1,829
-88% -$13.3K ﹤0.01% 5519
2025
Q2 		$12.8K Buy
2,089
+1,440
+222% +$12.6K ﹤0.01% 5149
2025
Q1 		$4.39K Buy
649
+647
+32,350% +$5.19K ﹤0.01% 5292
2024
Q4 		$16 Sell
2
-10,971
-100% -$89.5K ﹤0.01% 5756
2024
Q3 		$81.7K Buy
+10,973
New +$86.9K ﹤0.01% 4861

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Citigroup's ACTU Position: Q2 2026 in Review

Citigroup reduced its Actuate Therapeutics (ACTU) stake by 21% in Q2 2026, selling an estimated $239 and leaving 395 shares worth $604. The position accounts for ﹤0.01% of the portfolio, ranked #5447.

Citigroup first reported a position in ACTU in Q3 2024 and has held it in 8 quarters since. The position peaked at $81.7K in Q3 2024. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Citigroup held 395 shares of Actuate Therapeutics worth $604 as of Q2 2026.
  • Citigroup sold 103 Actuate Therapeutics shares in Q2 2026, an estimated $239.
  • Actuate Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5447 holding.
  • Citigroup first reported a position in Actuate Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Citigroup's Actuate Therapeutics position peaked at $81.7K in Q3 2024.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.